|
注册号: Registration number: |
ChiCTR2500106636 |
|
最近更新日期: Date of Last Refreshed on: |
2025-07-28 10:18:57 |
|
注册时间: Date of Registration: |
2025-07-28 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
针刺结合电脑辅助认知训练对脑卒中后失语症的疗效观察 |
|
Public title: |
Efficacy of Acupuncture Combined with Computer-Assisted Cognitive Training in Post-Stroke Aphasia |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
针刺“百会”、“神庭”结合电脑辅助认知训练对脑卒中后失语症的疗效观察 |
|
Scientific title: |
Efficacy of Acupuncture at Baihui and Shenting Combined with Computer-Assisted Cognitive Training in Post-Stroke Aphasia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
邱丽芳 |
研究负责人: |
邱丽芳 |
|
Applicant: |
Lifang Qiu |
Study leader: |
Lifang Qiu |
|
申请注册联系人电话: Applicant telephone: |
+86 159 6007 3045 |
研究负责人电话:
Study leader's |
+86 159 6007 3045 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
372743693@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
372743693@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省福州市鼓楼区湖东路13号 |
研究负责人通讯地址: |
福建省福州市鼓楼区湖东路13号 |
|
Applicant address: |
No. 13, East Hu Road, Gulou District, Fuzhou, Fujian |
Study leader's address: |
No. 13, East Hu Road, Gulou District, Fuzhou, Fujian |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
福建中医药大学附属康复医院 |
||
|
Applicant's institution: |
Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
福建中医药大学附属康复医院 |
||
|
Affiliation of the Leader: |
Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2019KY-024-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建中医药大学附属康复医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2020-01-02 00:00:00 | ||
|
伦理委员会联系人: |
修春英 |
||
|
Contact Name of the ethic committee: |
Chunying Xiu |
||
|
伦理委员会联系地址: |
福建省福州市鼓楼区湖东路13号 |
||
|
Contact Address of the ethic committee: |
No. 13, East Hu Road, Gulou District, Fuzhou, Fujian |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 591 8852 9125 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
福建中医药大学附属康复医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省福州市鼓楼区湖东路13号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 13, East Hu Road, Gulou District, Fuzhou, Fujian |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
福建科技计划项目 |
||||||||||||||||||||||
|
Source(s) of funding: |
Fujian Science and Technology Plan Project |
||||||||||||||||||||||
|
研究疾病: |
中风后失语症 |
||||||||||||||||||||||
|
Target disease: |
Post-stroke aphasia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
探讨针刺“百会”、“神庭”联合计算机辅助认知训练(acupuncture combined RehaCom,ACR)对脑卒中失语症患者语言及认知功能的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
To investigate the effect of acupuncture at Baihui (GV20) and Shenting (GV24) combined with RehaCom(ACR) on language and cognitive functions in patients with post-stroke aphasia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 其他疾病(如脑肿瘤、脑外伤、脑肿瘤等)引起失语症者; 2. 存在精神障碍影响语言认知检查者; 3. 伴有帕金森氏病,多发性硬化等其他神经系统退行性疾病者; 4. 存在听力或视力障碍导致无法配合评估与训练者; 5. 合并有心、肝、肾、内分泌系统和造血系统等严重疾病者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Aphasia caused by other diseases other than stroke, such as brain tumors or traumatic brain injury; 2. Presence of psychiatric disorders that interfere with language or cognitive assessment; 3. Coexisting neurodegenerative diseases such as Parkinson’s disease or multiple sclerosis; 4. People with severe hearing or visual impairments are unable to receive evaluation or therapy ; 5. Severe diseases of the cardiovascular, hepatic, renal, endocrine, or hematologic systems. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2019-07-01 00:00:00至 To 2022-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2020-01-05 00:00:00 至 To 2022-04-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机序列的产生: 使用 SPSS 21.0 生成随机数字序列。 由主要研究者进行操作。 随机分配: 将参与者按照 1:1 的比例分配到两个组别 (A 和 B),其中 A 组为对照组 (常规语言训练),B 组为治疗组 (常规语言训练+ACR 方案)。 将随机序列和组别分配信息安全存储并保密。 准备 80个不透明的棕色信封,每个信封对应一个参与者。 信封上依次编号,内部放置包含相应随机序列号和组别分配信息的纸条。 招募的参与者将严格按照纳入和排除标准进行筛选。 在确认符合条件后,指定的工作人员将按照信封编号的升序打开信封,揭示组别分配。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Prior to the commencement of the trial, we will utilize SPSS version 25.0 software to generate a random sequence of numbers, allocating participants into two groups (A and B) with a 1:1 ratio. Group A represents the treatment group, while Group B serves as the control group. The random sequence and group allocation information will be securely stored and kept confidential by the principal investigator. We will prepare 80 opaque brown envelopes corresponding to the number of participants to be enrolled. Each envelope will be sequentially numbered on the exterior. Inside each envelope, we will place a sheet containing the corresponding random sequence number and group allocation information. Participants will be strictly follow inclusion and exclusion criteria to determine eligibility. Upon confirmation of eligibility, a designated staff member will open the envelopes in ascending order of their numerical identifiers to reveal the group allocation. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
(1)针灸操作者、语言认知训练治疗师和参与者无法设盲: 由于针灸和计算机认知辅助训练治疗的特殊性,针灸操作者、语言认知训练治疗师、参与者无法做到双盲。参与者会知道自己接受的是常规治疗还是ACR 方案组,而针灸操作者、语言认知训练治疗师也无法避免知晓参与者所属的组别。 (2)评估者设盲: 语言认知功能评估者与统计分析的统计学家都将保持盲态,即他们不知道参与者所属的组别,从而避免主观因素对结果评估的影响。 |
|
Blinding: |
(1) Blinding cannot be applied to acupuncturists, language and cognitive training therapists, and participants: Due to the specificity of acupuncture and computer-assisted cognitive training treatments, it is impossible to achieve double blinding for acupuncturists, language and cognitive training therapists, and participants. Participants will be aware of whether they are receiving conventional treatment or are in the ACR (Computer-Assisted Cognitive Rehabilitation) protocol group, and acupuncturists and language and cognitive training therapists also cannot avoid knowing which group the participants belong to. (2) Blinding of evaluators: Both the evaluators of language and cognitive functions and the statisticians responsible for statistical analysis will remain blinded, thereby avoiding the influence of subjective factors on the result evaluation. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
时间约2026.12 ,平台为临床试验公共管理平台 ResMan (www.medresman.org) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Time: approximately December 2026 Platform: Clinical Trial Public Management Platform ResMan (www.medresman.org) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究采用病例记录表(CRF) (1)基本信息填写:按照研究方案要求,准确填写患者的基本人口学信息,如姓名拼音缩写(遵循特定规则,两字姓名填写两字拼音前两个字母,三字姓名填写三字首字母及第三字第二字母,四字姓名填写每一个字的首字母)、性别、年龄、出生日期、民族等。 (2)入选与排除标准相关信息:记录患者是否符合入选标准和排除标准的各项条件,对于涉及到的疾病诊断标准、语言认知评估得分等,要如实填写相应的检查结果和判断依据。 (3)研究过程信息记录: 1)不良事件记录:如实记录临床研究期间发生的所有不良事件,包括发生时间、严重程度、持续时间、采取的措施和转归等。如有严重不良事件发生,需及时报告本研究单位临床研究负责人,并在 CRF 中详细记录。 2)试验完成情况总结:涵盖患者末次治疗时间记录,以及试验期间不良事件有无、是否中止试验等关键信息。若患者中止试验,提供了不良事件、缺乏疗效等常见原因选项,还有 “其他” 及对应说明栏,可全面记录试验完成相关状况,为研究结果分析提供基础。 (4)填写规范: 1) 应用黑色签字笔用力填写,数据及用语务必准确、清晰,不得随意涂改。错误之处纠正时需用横线居中划出,并签署修改者姓名缩写及修改时间,勿用橡皮擦、修正液遮盖或划许多道线。 2) 所有选择项目的□内用 × 标注,所有应填写数字的□填写阿拉伯数字,缺省方框用 0 填写。对于因故 “未查或漏查” 的检验项目,填写 ND,并注明原因;“不知道” 则填入 “UK”;“不能提供” 或 “不适用” 则填入 “NA”。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study uses a Case Record Form (CRF). (1) Completion of Basic Information: Fill in the participants demographic information accurately in accordance with the requirements of the research protocol. This includes the abbreviation of the patient's name in pinyin, gender, age, date of birth, ethnicity, etc. (2) Information Related to Inclusion and Exclusion Criteria: Record whether the participant meets all the conditions of the inclusion and exclusion criteria. For disease diagnostic criteria and language assessment scores involved, fill in the corresponding test results and judgment bases truthfully. (3) Recording of Information during the Research Process: 1) Recording of Adverse Events: Record all adverse events that occur during the clinical research truthfully, including the occurrence time, severity, duration, measures taken, and outcomes. In case of serious adverse events, report them to the clinical research leader of this research unit in a timely manner and record them in detail in the CRF. 2) Summary of Trial Completion Status: This covers the recording of the patient's last treatment time, as well as key information such as the presence or absence of adverse events during the trial and whether the trial was terminated. If the participant terminates the trial, common reasons such as adverse events and lack of efficacy are provided as options, along with an "Other" option and a corresponding description column, which can comprehensively record the relevant status of trial completion and provide a basis for the analysis of research results. (4) Filling - in Specifications: 1) Use a black - ink pen and write firmly. Ensure that the data and language are accurate and clear. Do not alter the content casually. When correcting errors, cross out the incorrect part with a horizontal line in the middle, and sign the initials of the modifier and the modification time. Do not use erasers, correction fluids, or draw multiple lines to cover the errors. 2) For all check - box items, mark with "×" inside the □. For all boxes that require numerical filling, use Arabic numerals. Fill default boxes with "0". For test items that are "not examined or missed" for some reason, fill in "ND" and indicate the reason. Fill in "UK" for "unknown", and "NA" for "not available" or "not applicable". |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |